Abstract
This retrospective study evaluates the progression‐free interval and survival outcomes of 40 canine (Canis familiaris) patients with Patnaik grade II and III mast cell tumours treated with combination vinblastine, prednisolone and toceranib phosphate from 2011 to 2015. Patients were subdivided into three groups; patients who received neoadjuvant therapy for poorly operable lesions, patients who received adjuvant therapy following surgical resection and patients being palliated for gross metastatic disease. Median survival time (MST) for the neoadjuvant group was not reached. Median survival time for the remaining groups was 893 days and 218 days, respectively. This combination demonstrated response in 90% (26/29) patients with measurable disease. The predominant side effects related to this chemotherapy combination were gastrointestinal in origin. Further prospective studies are required to further validate the efficacy of this treatment protocol.
Highlights
Mast cell tumours (MCTs) are the most common cutaneous neoplasm of the dog, estimated to comprise 16–21% of these tumours
The primary aim of this study is to describe the response of MCTs to a standard combination of vinblastine, prednisolone and toceranib phosphate in a clinical setting and determine survival times and progression-free intervals for these patients
Medical records from 40 client owned dogs with MCTs treated with combination vinblastine, prednisolone and toceranib phosphate (Palladia; Zoetis) were selected
Summary
Mast cell tumours (MCTs) are the most common cutaneous neoplasm of the dog, estimated to comprise 16–21% of these tumours. Mast cell tumours vary greatly in their gross appearance, biologic behaviour and malignancy (Blackwood et al 2012). The aetiology of this disease remains poorly understood. Due to the large number of treatment options described in the veterinary literature for this common neoplasm, many controversies still remain regarding a gold standard of management. There has been little consensus on the efficacy of each treatment modality between studies. This makes developing a gold standard of treatment difficult
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
